Early Kalydeco Therapy Shown to Benefit 2 CF Infants: Case Study
Kalydeco (ivacaftor) therapy, given before age 1, was shown to normalize sweat chloride levels, and improve growth and lung and pancreas function in two baby boys with cystic fibrosis (CF), a case study reported. According to the researchers, these results show that Kalydeco “seems to be safe and…